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To the Editor: 
Gaining a better insight into the mechanisms governing intracellular lipid transport is 
of fundamental importance to medical science. Recently, Song and coworkers reported in Cell 
the existence of dynamic membrane contact sites between lysosomes and peroxisomes that 
mediate cholesterol transport from the former to the latter organelle (Chu et al., 2015). In 
addition, the authors argue that these contact sites are formed by interaction of lysosomal 
synaptotagmin VII (SYT7) with phosphatidylinositol 4,5 bisphosphate (PI(4,5)P2) on the 
peroxisomal membrane and that cholesterol is accumulating in cultured cells from patients 
and mice with diverse peroxisomal disorders. The authors employed an elegant genome-wide 
RNAi screen in HeLa cells to detect genes that affect cholesterol trafficking from lysosomes 
to the plasma membrane. To validate the unexpected enrichment of various genes involved in 
peroxisome biogenesis and metabolism, they designed an organelle co-precipitation method to 
identify components of, and functionally characterize, the lysosome-peroxisome membrane 
contacts observed by advanced microscopy at the biochemical level. However, to our surprise, 
this assay was based on the affinity capturing of peroxisomes in HeLa cells expressing EGFP-
His6-SKL on Ni-Sepharose. Indeed, given that SKL-tagged variants of EGFP are routinely 
used in the peroxisome field as bona fide marker proteins for the peroxisome lumen, EGFP-
His6-SKL is physically shielded from the Ni-affinity matrix by the peroxisomal membrane 
and cannot be used to study direct interactions between the peroxisomal and lysosomal 
compartments. As such, all conclusions deriving from this particular experimental setup need 
to be interpreted with care, including the cholesterol transfer from lysosomes to peroxisomes 
via (lysosomal) Syt7-(peroxisomal)PI(4,5)P2 membrane contact sites. Also, we are very 
puzzled by the authors’ observations that a knockdown of PEX1, PEX3, PEX6, PEX10, or 
PEX26 results in fewer peroxisome-lysosome contact sites and the accumulation of 
cholesterol, but not in a cytosolic mislocalization of EGFP-His6-SKL. Of course, the latter 
finding may be explained by the fact that residual amounts of these peroxins are sufficient to 
maintain a functional peroxisomal protein import machinery. However, if this is indeed the 
case, it may well be that the in cellulo decrease in lysosome-peroxisome contact sites can be 
attributed to a reduction in peroxisome number, a well-known consequence of PEX gene 
disruption (Steinberg et al., 2006), rather than to altered peroxisome properties. 
The authors translate their findings by showing massive cholesterol accumulation (as 
determined by filipin staining) in skin fibroblasts from patients with either peroxisome 
biogenesis defects or ABCD1 deficiency and in tissues of Abcd1 knockout mice. Here it is 
important to point out that other investigators have already reported that cholesterol is 
enriched in the late endosomal/lysosomal compartment of skin fibroblasts from peroxisome 
biogenesis disorder patients (Thai et al., 2001). Importantly, these authors link this 
abnormality to a deficiency in plasmalogens, ether phospholipids that depend on peroxisomes 
for their synthesis. Others have shown that plasmalogen deficiency, one of the biochemical 
hallmarks of malfunctioning peroxisomes, interferes with the transport of cholesterol from the 
plasma membrane or endocytic compartments to the endoplasmic reticulum in Chinese 
hamster ovary cells (Munn et al., 2003). Hence, it is essential to take into consideration that 
silencing of peroxins can affect the plasma membrane cholesterol content by routes other than 
cholesterol transport from lysosomes to peroxisomes. 
Concerning the findings related to ABCD1, a peroxisomal transporter necessary for 
import of a subset of substrates of the peroxisomal β-oxidation pathway, it is remarkable that 
no other essential peroxisomal β-oxidation enzymes were discovered in the screen nor tested 
in the validation assays, and that no logical links with a shortage of PI(4,5)P2 in the 
peroxisomal membrane were proposed. The authors’ assumption that perturbed cholesterol 
trafficking was overlooked as a key to the pathogenesis in ABCD1 and PEX gene-related 
disorders is worth further investigation. However, cholesterol metabolism was investigated 
intensively in ABCD1 deficiency in the 1970’s, subsequent to the discovery of the presence of 
very-long-chain fatty acid cholesterol esters in adrenals of X-ALD patients. To our 
knowledge, except for one, never confirmed publication (Burton & Nadler, 1974), no 
abnormalities in cholesterol metabolism were found in fibroblasts (Yavin et al., 1976). In 
addition, cholesterol levels were normal in liver and brain tissue of PEX-deficient mice 
(Vanhorebeek et al., 2001). Moreover, readers should be aware that there are vast differences 
between the phenotypes of ABCD1-, PEX- or NPC1-deficient patients and those of their 
respective mouse models. Finally, in contrast to what is stated by the authors, Abcd1 knockout 
mice do not develop CNS demyelination (Kemp et al., 2012). 
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